Lilly breaks ground on $3.5bn manufacturing site in Pennsylvania

At AHA 2026, data on new cardiometabolic therapies highlighted pharmacists' growing role. Survodutide (Zealand Pharma, Boehringer Ingelheim) showed cardiovascular safety. Enlicitide (Merck) sustained LDL-C reductions. Stanford's model embedded pharmacists in heart failure care. Orforglipron (Eli Lilly) lowered systolic blood pressure. Pharmacists were noted for their critical roles in titration, adherence, and monitoring.

Eli Lilly began construction on a $3.5B manufacturing site in Pennsylvania, part of a $50B U.S. expansion. The facility, operational by 2031, will create 850 jobs and produce injectable medicines. According to Governor Shapiro, this supports Pennsylvania's life sciences sector and economy.

Eli Lilly's partnership with Counsel Health for GLP-1 prescriptions may be affected by Oura's acquisition of Counsel. Lilly could gain a financial stake in Oura, with a $50 million stock purchase contingent on certain conditions, though these have not yet been met, according to STAT's Elaine Chen.

Eli Lilly began construction on a $3.5 billion manufacturing site in Pennsylvania, part of a $50 billion U.S. expansion. The facility, operational by 2031, will produce obesity treatments, including retatrutide. The project is expected to create 850 high-wage jobs and 2,000 construction jobs, with Lilly committing $1 million over five years to community initiatives.

Eli Lilly began construction on a $3.5B manufacturing facility in Upper Macungie Township, PA, marking the largest economic development investment in the Lehigh Valley and Pennsylvania's life sciences sector. The project, expected to create 2,000 construction jobs and 800 permanent positions by 2029, is part of Lilly's $50B US expansion plan. CEO David Ricks highlighted the facility's role in scaling production of obesity treatments, including retatrutide.

Eli Lilly (LLY) shares rose 0.35% to $1,442.39 after China approved its weight-loss pill, orforglipron. The approval opens a large market, with China estimating 65% of its population may be overweight or obese by 2030. Lilly faces competition from Novo Nordisk, Pfizer, and Innovent Biologics. The stock's initial 2.8% premarket gain faded, suggesting the approval was anticipated. Analysts note execution and pricing will be key for future performance.